Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$51.35

-0.29 (-0.56%)

, CELG

Celgene

$90.71

0.03 (0.03%)

09:10
02/20/19
02/20
09:10
02/20/19
09:10

Bristol-Myers sees 'meaningful financial benefits' from Celgene transaction.

Bristol-Myers Squibb (BMY) said an updated its investor presentation about the Celgene (CELG) transaction. The company said, "The Celgene transaction is the natural next step in Bristol-Myers Squibb's proven strategy that has consistently delivered results for over a decade. Through a disciplined approach to driving innovation, focusing on high-value opportunities and sourcing innovation externally to complement its internal portfolio and pipeline, Bristol-Myers Squibb has generated consistently strong growth and increased its dividend for 10 consecutive years. The combination with Celgene will create a leading biopharma with increased scale, while maintaining the same agility and a focus on delivering for patients in core disease areas of high-unmet medical need. The pipeline of the combined company provides significant near-, medium- and long-term opportunities for value creation. Bristol-Myers Squibb is acquiring Celgene's robust and complementary pipeline at an attractive price. In addition to six expected near-term product launches representing more than $15B in revenue potential, the combination will greatly increase Bristol-Myers Squibb's Phase I and II assets, which will provide the next set of registrational opportunities in core therapeutic areas. With an expanded set of scientific platforms and research capabilities, Bristol-Myers Squibb will be well positioned to discover and develop highly innovative medicines and accelerate these new options to patients through one of the highest-performing commercial organizations in the industry. Bristol-Myers Squibb is well positioned for 2025 and beyond with continued leadership across Oncology and a diversified portfolio of assets. The combined company will have a broad, balanced and earlier life-cycle marketed portfolio with a significantly higher number of opportunities across multiple diseases to drive the growth of Bristol-Myers Squibb in the second half of the decade. These opportunities will support financial strength for continued investment and innovation. The Celgene transaction is expected to generate meaningful financial benefits for all stockholders. With more than $45B of expected free cash flow generation over the first three full years post-closing, the combination will enable rapid debt reduction to de-lever the balance sheet and strengthen Bristol-Myers Squibb's credit profile. Bristol-Myers Squibb expects to realize run-rate cost synergies of approximately $2.5B by 2022 from the combination, and the combined company is expected to grow revenue and EPS every year through 2025."

BMY

Bristol-Myers

$51.35

-0.29 (-0.56%)

CELG

Celgene

$90.71

0.03 (0.03%)

  • 20

    Feb

  • 28

    Feb

  • 18

    May

  • 20

    May

BMY Bristol-Myers
$51.35

-0.29 (-0.56%)

01/23/19
MZHO
01/23/19
NO CHANGE
Target $81
MZHO
Buy
Mizuho sees 'significant upside' in Nektar shares, reiterates $81 price target
While shares of Nektar Therapeutics (NKTR) have performed strongly year-to-date, "significant upside remains," Mizuho analyst Difei Yang tells investors in a research note. A recent Nature article on IL-2 immunotherapy and new players in the field provide support for Nektar's approach to immuno-oncology, says Yang. Further, she believes the company's collaborations with large pharma, including Bristol-Myers Squibb (BMY) and Pfizer, underscore the "strong potential" of NKTR-214. With multiple data readouts expected in 2019, Yang sees "significant value" in Nektar shares. She reiterates a Buy rating on the name with an $81 price target. The stock closed yesterday down 3% to $44.76.
01/24/19
ADAM
01/24/19
NO CHANGE
Target $161
ADAM
Buy
Bluebird Bio's bb2121 'too valuable' for Bristol-Myers to share, says Canaccord
Assuming that the Bristol-Myers (BMY) and Celgene (CELG) transaction closes, Canaccord analyst John Newman said he expects Bristol-Myers will seek 100% control of bb2121 from Bluebird Bio (BLUE), calling the treatment "too valuable" to share due to the large long-term commercial potential and Bristol's deep expertise in commercialization. Stating that Bristol-Myers could try to acquire 100% control of bb2121 from Bluebird via a buyout, U.S. royalty, or higher EU royalty, Newman added that Bristol and Celgene do not have right of first refusal if an acquirer were to tender an offer, which he calls a "favorable setup" for Bluebird shareholders. The analyst, who estimates a Bluebird buyout to obtain the other half of the company could be valued at $8.8B-$10.5B, keeps a Buy rating and $161 price target on Bluebird Bio shares.
02/01/19
JEFF
02/01/19
DOWNGRADE
Target $95
JEFF
Hold
Celgene downgraded to Hold from Buy at Jefferies
Jefferies analyst Michael Yee reiterated his view that Bristol-Myers Squibb's (BMY) acquisition of Celgene (CELG) should continue on track and will likely close, though he noted that the spread has come in and that Celgene's comments on its earnings call suggest the potential for an earlier rather than later than expected closing of the deal. Yee keeps a $95 price target on Celgene shares, but downgrade the stock to Hold from Buy given that the upside he sees from current levels is less than 15%.
02/11/19
GUGG
02/11/19
NO CHANGE
GUGG
Neutral
Patent ruling positive for Celgene and Bristol-Myers, says Guggenheim
Guggenheim analyst Seamus Fernandez said the Patent Trial and Appeal Board's decision denying Dr. Reddy's (RDY) inter partes review petition seeking to invalidate 3 Revlimid myelodysplastic syndrome patents expiring April 2023 is a positive for Celgene's (CELG) shareholders as well as for the combination with Bristol-Myers (BMY). Consistent with his below-consensus estimates for Revlimid, he continues to view a broad settlement, beginning with Dr. Reddy's, as the most likely outcome, Fernandez tells investors. He keeps a Neutral rating on Bristol-Myers shares.
CELG Celgene
$90.71

0.03 (0.03%)

01/31/19
RILY
01/31/19
UPGRADE
Target $3.25
RILY
Buy
B. Riley FBR upgrades Geron to Buy ahead of pivotal Phase III trial
B. Riley FBR analyst George Zavoico upgraded Geron (GERN) to Buy from Neutral and raised his price target for the shares to $3.25 from $1.50. The analyst believes investors should focus on the pivotal Phase III trial of imetelstat. Geron is initiating the pivotal portion of its Phase 3 trial in mid-year, which could lead to FDA approval in 2023, says Zavoico. He sees U.S. sales reaching $250M in 2024 and $750M in 2026. The drug "could meet an unmet medical need and provide a meaningful clinical benefit" for myelodysplastic syndrome patients, Zavoicotells investors in a research note. He expects both imetelstat and Celgene (CELG) and Acceleron's (XLRN) Luspatercept to be approved for MDS and be "widely used in treating mostly different subgroups." Shares of Geron are up 11%, or 11c, to $1.14 in premarket trading.
01/31/19
PIPR
01/31/19
NO CHANGE
PIPR
Celgene reports 'solid' Q4, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond maintained a Neutral rating and $85 price target on Celgene shares after the company reported "solid" Q4 results, with all major brands -- Revlimid, Pomalyst, Abraxane and Otezla -- performing better than consensus, and timelines for ozanimod, liso-cel, and bb2121 still looking to be on track. Celgene also reiterated its FY19 guidance, which the analyst noted was generally in-line with the firm's estimates.

TODAY'S FREE FLY STORIES

ITW

Illinois Tool Works

$155.05

-0.91 (-0.58%)

, HON

Honeywell

$168.42

1.7 (1.02%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Downgrade
Illinois Tool Works, Honeywell rating change  »

Illinois Tool Works…

ITW

Illinois Tool Works

$155.05

-0.91 (-0.58%)

HON

Honeywell

$168.42

1.7 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

04:55
09/23/19
09/23
04:55
09/23/19
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

HR

Healthcare Realty Trust

$33.17

-0.155 (-0.47%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Healthcare Realty Trust management to meet with Capital One »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

NBIX

Neurocrine

$100.74

-0.77 (-0.76%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Neurocrine participates in a conference call with JPMorgan »

SMid Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

SIBN

SI-Bone

$20.18

0.28 (1.41%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
SI-Bone management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

TXN

Texas Instruments

$126.70

-2.1 (-1.63%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Texas Instruments management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

04:55
09/23/19
09/23
04:55
09/23/19
04:55
General news
PMI Composite FLASH â€' Level to be reported at 09:45 »

September PMI Composite…

CLDR

Cloudera

$9.00

0.33 (3.81%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Cloudera management to meet with Needham »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 25

    Sep

IMAX

Imax

$21.83

0.04 (0.18%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Recommendations
Imax analyst commentary  »

Imax management to meet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

KNSL

Kinsale Capital Group

$99.46

-1.68 (-1.66%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Kinsale Capital Group management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

04:55
09/23/19
09/23
04:55
09/23/19
04:55
General news
PMI Composite FLASH Manufacturing â€' Level to be reported at 09:45 »

September PMI Composite…

HKMPY

Hikma

$0.00

(0.00%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Hikma participates in a conference call with JPMorgan »

European Pharma Equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Sep

  • 25

    Sep

DNOW

NOW Inc.

$12.05

-0.055 (-0.45%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
NOW Inc. management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 06

    Nov

  • 11

    Nov

  • 12

    Nov

  • 13

    Nov

04:55
09/23/19
09/23
04:55
09/23/19
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

PRGO

Perrigo

$55.29

0.995 (1.83%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Perrigo management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 01

    Oct

BRKR

Bruker

$43.62

0.06 (0.14%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Bruker management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

BABA

Alibaba

$182.43

1.96 (1.09%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Alibaba management to meet with KeyBanc »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

ETSY

Etsy

$60.39

1.34 (2.27%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Etsy management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

SPOT

Spotify

$120.73

-3.685 (-2.96%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Spotify management to meet with Morgan Stanley »

Group Breakfast Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

WTTR

Select Energy Services

$9.02

0.11 (1.23%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Select Energy Services management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

04:55
09/23/19
09/23
04:55
09/23/19
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

August Chicago Fed…

UPS

UPS

$120.71

1.61 (1.35%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
UPS management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

BPOP

Popular

$54.57

0.02 (0.04%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Popular management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 13

    Nov

MTDR

Matador

$17.04

0.25 (1.49%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Matador management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

CPE

Callon Petroleum

$4.53

-0.015 (-0.33%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Callon Petroleum management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 02

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.